N,N-Dipropyl-isobutyramide | 6282-99-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-Dipropyl-isobutyramide
• 英文别名: 2-Methyl-n,n-dipropylpropanamide
• CAS: 6282-99-1
• 化学式: C₁₀H₂₁NO
• mdl: MFCD01214222
• 分子量: 171.283
• InChiKey: XYEFHKQZJINXJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N,N-di-n-propyl(methaneyl)propenamide 在 hexacarbonyl molybdenum 、 苯硅烷 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以70%的产率得到N,N-Dipropyl-isobutyramide
  参考文献：
  名称：

  Silicon hydrides and molybdenum(0) catalyst: a novel approach for conjugate reduction of .alpha.,.beta.-unsaturated carbonyl compounds

  摘要：

  DOI：

  10.1021/jo00388a042

文献信息

• PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES
  申请人：Blumberg Laura Cook

  公开号：US20110319422A1

  公开（公告）日：2011-12-29

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

  该发明提供了一种持续释放内酰胺、亚酰胺、酰胺、磺胺、碳酸酯或尿素含有母药的方法，通过向患者施用该发明的一种前药化合物的有效量，在向患者施用后，从前药中释放母药是持续释放的。适用于该发明方法的前药化合物是母药的不稳定结合物，通过羰基连接的前药基团进行衍生化。该发明的前药化合物可用于治疗任何需要内酰胺、亚酰胺、酰胺、磺胺、碳酸酯或尿素含有母药作为治疗的情况。
• [EN] ANTIBODY CONSTRUCT-DRUG CONJUGATE FOR THE TREATMENT OF HEPATITIS<br/>[FR] CONJUGUÉ DE CONSTRUCTION D'ANTICORPS-MÉDICAMENT POUR LE TRAITEMENT DE L'HÉPATITE
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2019118884A1

  公开（公告）日：2019-06-20

  Various compositions are disclosed for the treatment of viral infections. The compositions comprise antibody constructs directed to the liver, attached to myeloid cell agonists, specifically TLR7 and TLR8 agonists, via a linker. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating viral infections, such as viral liver diseases.

  披露了用于治疗病毒感染的多种组合物。这些组合物包括针对肝脏的抗体构建体，通过连接器与髓系细胞激动剂连接，特别是TLR7和TLR8激动剂。另外还提供了这些偶联物的制备和使用方法。这包括治疗病毒感染的方法，例如病毒性肝脏疾病。
• Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20150320875A1

  公开（公告）日：2015-11-12

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

  本发明提供了一种持续释放内酰胺、亚胺、酰胺、磺酰胺、氨基甲酸酯或尿素含量的母药的方法，通过向患者施用本发明的前药化合物的有效量，在患者体内释放母药的速率是持续释放的。适用于本发明方法的前药化合物是通过羰基偶联的前药基团衍生的母药的不稳定结合物。本发明的前药化合物可用于治疗任何需要内酰胺、亚胺、酰胺、磺酰胺、氨基甲酸酯或尿素含量的母药治疗的疾病。
• Thiazole Derivatives as Alpha 7 NACHR Modulators
  申请人：LUPIN LIMITED

  公开号：US20150299178A1

  公开（公告）日：2015-10-22

  Disclosed is a compound of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its pharmaceutical composition, and its combinations with suitable medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

  公开了一种化合物的式子(I)，其中R1、R2、R3、R4、R5和m如此描述，作为尼古丁乙酰胆碱受体特别是α7亚型的调节剂，其互变异构体，其立体异构体，其药学上可接受的盐，其药物组合物，以及其与适当药物的组合物。还公开了一种制备该化合物的方法以及在治疗中的预期用途，特别是在防治阿尔茨海默病、轻度认知障碍、老年性痴呆等疾病中。
• [EN] CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF<br/>[FR] COMPOSÉS MODULATEURS DE CFTR, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：ILDONG PHARMACEUTICAL CO LTD

  公开号：WO2022084741A1

  公开（公告）日：2022-04-28

  CFTR modulator compounds and compositions including said compounds are provided. The present disclosure also provides PDE4 inhibiting compounds and compositions including said compounds. Also provided are methods of using said compounds and compositions for modulating CFTR, methods for treating an eye disease or disorder and methods for treating CFTR-related indications. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE4, for treating an inflammatory disease or disorder and for treating other PDE4-related indications. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

  本文提供了CFTR调节剂化合物和包括该化合物的组合物。本文还提供了PDE4抑制剂化合物和包括该化合物的组合物。此外，本文还提供了使用该化合物和组合物调节CFTR的方法，治疗眼部疾病或疾病的方法，以及治疗CFTR相关症状的方法。本文还提供了使用该化合物和组合物抑制PDE4，治疗炎症性疾病或疾病的方法，以及治疗其他PDE4相关症状的方法。此外，本文还提供了制备该化合物和组合物的方法，以及该化合物的合成前体。